Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Public Health Nursing (Boston, Mass.)|March 13, 2025
Development of the Essential Individual Care Needs Assessment Tool for Public Health NursesKyoko Yoshioka-Maeda, Hiroshige Matsumoto, Chikako Honda, et al.
American Journal of Hematology|October 6, 2007
Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumabShinichi Kako, Yoshinobu Kanda, Kumi Oshima, et al.
American Journal of Hematology|October 6, 2007
Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood levelKumi Oshima, Yoshinobu Kanda, Hideki Nakasone, et al.
The Journal of Antimicrobial Chemotherapy|June 23, 2007
Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipientsKumi Oshima, Yoshinobu Kanda, Yuki Asano-Mori, et al.
International Journal of Hematology|March 6, 2008
Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantationYuki Asano-Mori, Yoshinobu Kanda, Kumi Oshima, et al.
American Journal of Hematology|February 13, 2008
Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantationYuki Asano-Mori, Yoshinobu Kanda, Kumi Oshima, et al.
The Journal of Antimicrobial Chemotherapy|December 7, 2007
False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantationYuki Asano-Mori, Yoshinobu Kanda, Kumi Oshima, et al.
Gynecologic Oncology|April 28, 2015
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancerAki Miyasaka, Katsutoshi Oda, Yuji Ikeda, et al.
Haematologica|July 7, 2018
Prognostic factors of Erdheim-Chester disease: a nationwide survey in JapanTakashi Toya, Mizuki Ogura, Kazuhiro Toyama, et al.
BMC Cancer|March 15, 2014
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cellsAki Miyasaka, Katsutoshi Oda, Yuji Ikeda, et al.
Pageof 6